Neurogene INC Schedule 13G passive stakes

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 818,706 shares, representing 5.18% of Neurogene Inc.'s common stock as of June 30, 2026.

Trails Edge Capital Partners, LP, along with its affiliates, has reported a 5.1% beneficial ownership stake in Neurogene Inc.'s common stock.

EcoR1 Capital, LLC and its affiliates reported a 9.9% beneficial ownership stake in Neurogene Inc. common stock, including shares and warrants, as detailed in an amended Schedule 13G filing.

Commodore Capital LP and Commodore Capital Master LP have disclosed a 3.0% beneficial ownership stake in Neurogene Inc., totaling 427,866 common shares as of June 30, 2025.

Baker Bros. Advisors and its principals have disclosed a 7.0% beneficial ownership stake in Neurogene Inc., holding nearly one million shares of common stock.

Baker Bros. Advisors LP and its affiliates have disclosed a beneficial ownership of approximately 9.95% in Neurogene Inc.'s common stock as of March 31, 2025, through a Schedule 13G filing.

FMR LLC and its affiliates, along with Abigail P. Johnson, have filed an amended Schedule 13G disclosing a passive beneficial ownership of 3.1% of Neurogene Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.8% beneficial ownership stake in Neurogene Inc.'s common stock as of March 31, 2025.

Redmile Group, LLC and its affiliates, including Jeremy C. Green and Redmile Biopharma Investments I, L.P., have filed an amended Schedule 13G, confirming their beneficial ownership of 9.9% of Neurogene Inc.'s common stock as of December 31, 2024.

Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly disclosed a passive beneficial ownership of 2.98% of Neurogene Inc.'s common stock as of December 31, 2024.

Casdin Capital, LLC and affiliated entities have filed an amended Schedule 13G, revealing a beneficial ownership of 8.7% in Neurogene Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing that it no longer holds any beneficial ownership in Neurogene Inc., effectively divesting its entire stake.

RTW Investments, LP and Roderick Wong, M.D. have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Neurogene Inc.'s common stock as of December 31, 2024.